Surrey Heartlands

Joint Formulary & PAD

Insulin detemir - Diabetes Mellitus

You are here : Home > Formulary Search > Insulin detemir - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Cartridges
  • Pre-filled pen
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Levemir (insulin detemir Penfill / FlexPen) is being discontinued. Supplies are expected to run out by Dec 2026. It is recommended that this is not initiated in new patients.

Documentation

Guidelines (Local)
SDCCG - Insulin initiation in Type 2 Diabetes Guidelines - Sep 2014
Safety Information
Cutaneous amyloidosis - MHRA alert - guidance for healthcare professionals - Dec 2020

PAD Profile

ChemicalSubstance :
Insulin detemir
Indication :
Diabetes Mellitus
Group Name :
Insulin
Keywords :
long acting Insulin analogues, lipohypertrophy, cutaneous amyloidosis
Brand Names Include :
Levemir
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Diabetes Mellitus
Supporting Documents :
2

Other Indications

Below are listed other indications that Insulin detemir is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.

Committee Recommendations (2)

14 Jul 21 - Surrey Heartlands Medicines Safety Committee (MSC)

MHRA Safety Alert

Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site.  Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.

Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below

10 Jun 11 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The committee noted the high use of insulin analogues across Surrey (this is a national QIPP initiative but Surrey are particularly high prescribers). It was agreed that NPH insulins would be used first line but there were indications when analogues would be appropriate - see policy statement